8-KLeadership Changes

Medtronic plc 8-K Report, Executive Changes (Mar 17, 2025)

Filed March 17, 2025For Securities:MDT

Summary

Medtronic plc (MDT) announced a leadership transition within its finance department. Jennifer M. Kirk, the Global Controller and Principal Accounting Officer, has resigned effective May 2, 2025, to pursue a CEO role at a private company, Exubrion Therapeutics. Investors should note that Ms. Kirk's departure is not attributed to any disagreements regarding Medtronic's operations or policies. To ensure a seamless handover, Denise L. Blomquist, currently the Assistant Global Controller, has been appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025. Ms. Blomquist brings extensive experience to the role, having been with Medtronic for 21 years in various finance positions. Her compensation will align with industry standards, including participation in the company's incentive and long-term incentive plans.

Key Highlights

  • 1Principal Accounting Officer Jennifer M. Kirk to resign effective May 2, 2025.
  • 2Ms. Kirk's resignation is voluntary and not due to any disagreements with Medtronic.
  • 3Denise L. Blomquist appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025.
  • 4Ms. Blomquist has 21 years of experience within Medtronic's finance organization.
  • 5Ms. Blomquist's compensation will be commensurate with her role and include participation in Medtronic's incentive plans.
  • 6No family relationships or reportable transactions exist between Ms. Blomquist and Medtronic's directors or executive officers.

Frequently Asked Questions

Jennifer M. Kirk is resigning to become the chief executive officer of Exubrion Therapeutics, a privately held company. Her resignation is stated to be voluntary and not a result of any disagreements regarding Medtronic's operations, policies, or practices.

Denise L. Blomquist, who currently serves as the Assistant Global Controller, has been appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025.

Ms. Blomquist has been employed at Medtronic since 2004, accumulating 21 years of experience within the finance organization in roles of increasing responsibility.

Yes, Ms. Kirk will remain with Medtronic through May 2, 2025, to support a smooth transition to Ms. Blomquist.